{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T12:29:15Z","timestamp":1793104155444,"version":"4.5.0"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1097\/mol.0b013e328351b439","type":"journal-article","created":{"date-parts":[[2012,2,10]],"date-time":"2012-02-10T04:16:57Z","timestamp":1328847417000},"page":"235-240","source":"Crossref","is-referenced-by-count":80,"title":["Phospholipase A2 enzymes in metabolic and cardiovascular diseases"],"prefix":"10.1097","volume":"23","author":[{"given":"David Y.","family":"Hui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-11-20211004","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1161\/CIRCULATIONAHA.110.936393","article-title":"Lipoprotein-associated and secreted phospholipase A2 in cardiovascular disease. Roles as biological effectors and biomarkers.","volume":"122","author":"Mallat","year":"2010","journal-title":"Circulation"},{"key":"R2-11-20211004","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.biochi.2010.02.002","article-title":"Extracellular phospholipases in atherosclerosis.","volume":"92","author":"Karabina","year":"2010","journal-title":"Biochimie"},{"key":"R3-11-20211004","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/jb\/mvr088","article-title":"Secreted phospholipase A2 revisited.","volume":"150","author":"Murakami","year":"2011","journal-title":"J Biochem"},{"key":"R4-11-20211004","doi-asserted-by":"crossref","first-page":"S231","DOI":"10.1194\/jlr.R800096-JLR200","article-title":"Signal-activated phospholipase regulation of leukocyte chemotaxis.","volume":"50","author":"Cathcart","year":"2009","journal-title":"J Lipid Res"},{"key":"R5-11-20211004","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/sj.ejhg.5201551","article-title":"Linkage and potential association of obesity-related phenotypes with two genes on chromosome 12q24 in a female dizygous twin cohort.","volume":"14","author":"Wilson","year":"2006","journal-title":"Eur J Hum Genet"},{"key":"R6-11-20211004","first-page":"E994","article-title":"Protection against diet-induced obesity and obesity-related insulin resistance in Group 1B PLA2-deficient mice.","volume":"283","author":"Huggins","year":"2002","journal-title":"Am J Physiol"},{"key":"R7-11-20211004","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/ijo.2010.215","article-title":"Pancreatic acinar cell-specific overexpression of group 1B phospholipase A2 exacerbates diet-induced obesity and insulin resistance in mice.","volume":"35","author":"Cash","year":"2011","journal-title":"Int J Obes"},{"key":"R8-11-20211004","doi-asserted-by":"crossref","first-page":"935","DOI":"10.2337\/diabetes.55.04.06.db05-1286","article-title":"Group 1B phospholipase A2-mediated lysophospholipid absorption directly contributes to postprandial hyperglycemia.","volume":"55","author":"Labonte","year":"2006","journal-title":"Diabetes"},{"key":"R9-11-20211004","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1096\/fj.09-144436","article-title":"Postprandial lysophospholipid suppresses hepatic fatty acid oxidation: the molecular link between group 1B phospholipase A2 and diet-induced obesity.","volume":"24","author":"Labonte","year":"2010","journal-title":"FASEB J"},{"key":"R10-11-20211004","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1194\/jlr.M019463","article-title":"Group 1B phospholipase A2 deficiency protects against diet-induced hyperlipidemia in mice.","volume":"52","author":"Hollie","year":"2011","journal-title":"J Lipid Res"},{"key":"R11-11-20211004","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1042\/bj2600207","article-title":"Lysophosphatidylcholine metabolism and lipoprotein secretion by cultured rat hepatocytes deficient in choline.","volume":"260","author":"Robinson","year":"1989","journal-title":"Biochem J"},{"key":"R12-11-20211004","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.bbalip.2008.04.012","article-title":"Metformin reduces cellular lysophosphatidylcholine and thereby may lower apolipoprotein B secretion in primary human hepatocytes.","volume":"1781","author":"Wanninger","year":"2008","journal-title":"Biochim Biophys Acta"},{"key":"R13-11-20211004","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1111\/j.1476-5381.2009.00308.x","article-title":"The Phospholipase A2 inhibitor methyl indoxam suppresses diet-induced obesity and glucose intolerance in mice.","volume":"157","author":"Hui","year":"2009","journal-title":"Br J Pharmacol"},{"key":"R14-11-20211004","doi-asserted-by":"crossref","first-page":"48535","DOI":"10.1074\/jbc.M205855200","article-title":"Interfacial Kinetic and binding properties of the complete set of human and mouse groups I, II, V, X, and XII secreted phospholipases A2.","volume":"277","author":"Singer","year":"2002","journal-title":"J Biol Chem"},{"key":"R15-11-20211004","doi-asserted-by":"crossref","first-page":"25024","DOI":"10.1074\/jbc.M313019200","article-title":"Arachidonic acid release from mammalian cells transfected with human group IIA and X secreted phospholipase A2 occurs predominantly during the secretory process and with the involvement of cytosolic phospholipase A2.","volume":"279","author":"Mounier","year":"2004","journal-title":"J Biol Chem"},{"key":"R16-11-20211004","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/nature01023","article-title":"Protective role of phospholipid oxidation products in endotoxin-induced tissue damage.","volume":"419","author":"BockKov","year":"2002","journal-title":"Nature"},{"key":"R17-11-20211004","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1161\/01.CIR.103.20.2495","article-title":"Adenovirus-mediated gene transfer of human platelet-activating factor-acetylhydrolase prevents injury-induced neointima formation and reduces spontaneous atherosclerosis in apolipoprotein E-deficient mice.","volume":"103","author":"Quarck","year":"2001","journal-title":"Circulation"},{"key":"R18-11-20211004","doi-asserted-by":"crossref","first-page":"e23425","DOI":"10.1371\/journal.pone.0023425","article-title":"W-y, Zhang J, Wu W-y, et al. Inhibition of lipoprotein-associated phospholipase A2 ameliorates inflammation and decreases atherosclerotic plaque formation in apoE-deficient mice.","volume":"6","year":"2011","journal-title":"PLoS One"},{"key":"R19-11-20211004","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/HCO.0b013e32832bcb22","article-title":"Lipoprotein-associated phospholipase A2 as a biomarker of coronary heart disease and a therapeutic target.","volume":"24","author":"Packard","year":"2009","journal-title":"Curr Opin Cardiol"},{"key":"R20-11-20211004","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.atherosclerosis.2011.09.019","article-title":"Decreased circulating lipoprotein-associated phospholipase A2 levels are associated with coronary plaque regression in patients with acute coronary syndrome.","volume":"219","author":"Dohi","year":"2011","journal-title":"Atherosclerosis"},{"key":"R21-11-20211004","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.jdiacomp.2006.07.004","article-title":"The role of lipoprotein-associated phospholipase A2 in the metabolic syndrome and diabetes.","volume":"20","author":"Noto","year":"2006","journal-title":"J Diabetes Complications"},{"key":"R22-11-20211004","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1038\/nm.1870","article-title":"Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development.","volume":"14","author":"Wilensky","year":"2008","journal-title":"Nat Med"},{"key":"R23-11-20211004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1517\/13543770903463905","article-title":"Phospholipase A2 inhibitors as potential therapeutic agents for the treatment of inflammatory diseases.","volume":"20","author":"Magrioti","year":"2009","journal-title":"Expert Opin Ther Patents"},{"key":"R24-11-20211004","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s13167-011-0063-4","article-title":"Lipoprotein associated phospholipase A2: role in atherosclerosis and utility as a biomarker for cardiovascular risk.","volume":"2","author":"Colley","year":"2011","journal-title":"EPMA J"},{"key":"R25-11-20211004","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1161\/01.ATV.19.5.1284","article-title":"Role of group II secretory phospholipase A2 in atherosclerosis: 1. Increased atherogenesis and altered lipoproteins in transgenic mice expressing group IIa phospholipase A2.","volume":"19","author":"Ivandic","year":"1999","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R26-11-20211004","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1161\/01.ATV.0000051701.90972.E5","article-title":"Macrophage-expressed group IIA secretory phospholipase A2 increases atherosclerotic lesion formation in LDL receptor-deficient mice.","volume":"23","author":"Webb","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R27-11-20211004","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/00041433-200010000-00004","article-title":"Phospholipase A2 and small dense low density lipoproteins.","volume":"11","author":"Hurt-Camejo","year":"2000","journal-title":"Curr Opin Lipidol"},{"key":"R28-11-20211004","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1194\/jlr.M400469-JLR200","article-title":"Macrophage-specific expression of group IIA sPLA2 results in accelerated atherogenesis by increasing oxidative stress.","volume":"46","author":"Tietge","year":"2005","journal-title":"J Lipid Res"},{"key":"R29-11-20211004","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1021\/bi062119b","article-title":"Recombinant production and properties of binding of the full set of mouse secreted phospholipases A2 to the mouse M-type receptor.","volume":"46","author":"Rouault","year":"2007","journal-title":"Biochemistry"},{"key":"R30-11-20211004","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0021-9150(96)05946-1","article-title":"Expression of secretory group II phospholipase A2 by CD1a positive cells in human atherosclerotic plaques.","volume":"127","author":"Bobryshev","year":"1996","journal-title":"Atherosclerosis"},{"key":"R31-11-20211004","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1096\/fj.05-5514fje","article-title":"Activation of sPLA2-IIA and PGE2 production by high mobility group protein B1 in vascular smooth muscle cells sensitized by IL-1ss.","volume":"20","author":"Jaulmes","year":"2006","journal-title":"FASEB J"},{"key":"R32-11-20211004","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1210\/jc.2009-1222","article-title":"Secretory type II phospholipase A2 Is produced and secreted by epicardial adipose tissue and overexpressed in patients with coronary artery disease.","volume":"95","author":"Dutour","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"R33-11-20211004","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s11745-010-3502-4","article-title":"COX2 inhibition and inhibition of cytosolic phospholipase A2 increase CD36 expression and foam cell formation in THP-1 cells.","volume":"46","author":"Anwar","year":"2011","journal-title":"Lipids"}],"container-title":["Current Opinion in Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00041433-201206000-00011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:37:46Z","timestamp":1786048666000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00041433-201206000-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/mol.0b013e328351b439","relation":{},"ISSN":["0957-9672"],"issn-type":[{"value":"0957-9672","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6]]}}}